Previous Article | Next Article ![]()
Journal of Virology, December 2000, p. 11153-11161, Vol. 74, No. 23
Division of Viral and Rickettsial Diseases,
National Center for Infectious Diseases, Centers for Disease Control
and Prevention, Atlanta, Georgia 30333,1 and
National Vaccine and Serum Institute, Beijing
100024,2 and National Poliovirus
Reference Center, Institute of Virology, Chinese Academy of
Preventive Medicine, Beijing 100052,3 People's
Republic of China
Received 24 July 2000/Accepted 13 September 2000
Type 1 wild-vaccine recombinant polioviruses were isolated from
poliomyelitis patients in China from 1991 to 1993. We compared the
sequences of 34 recombinant isolates over the 1,353-nucleotide (nt)
genomic interval (nt 2480 to 3832) encoding the major capsid protein,
VP1, and the protease, 2A. All recombinants had a 367-nt block of
sequence (nt 3271 to 3637) derived from the Sabin 1 oral poliovirus
vaccine strain spanning the 3'-terminal sequences of VP1 (115 nt) and the 5' half of 2A (252 nt). The remaining VP1 sequences were
closely (up to 99.5%) related to those of a major genotype of wild
type 1 poliovirus endemic to China up to 1994. In contrast, the
non-vaccine-derived sequences at the 3' half of 2A were more distantly
related (<90% nucleotide sequence match) to those of other
contemporary wild polioviruses from China. The vaccine-derived
sequences of the earliest (April 1991) isolates completely matched
those of Sabin 1. Later isolates diverged from the early isolates
primarily by accumulation of synonymous base substitutions (at a rate
of ~3.7 × 10 Polioviruses are among the most
rapidly evolving viruses known. The most important mechanism for the
rapid evolution of RNA viruses is a high rate of base misincorporation
by the viral RNA polymerases, which generally lack 3' A second important mechanism for generating sequence diversity among
picornaviruses is recombination (1, 25, 38, 44), first
described with polioviruses (18). Because the frequency of
genetic exchange is correlated with the extent of sequence homology
among templates (24, 41), recombination occurs among closely
related templates at high frequencies but can be unambiguously demonstrated only under well-controlled experimental conditions (4, 24). Natural recombination is most readily recognized when genetic exchanges occur between templates lacking close sequence similarities. Natural recombination in polioviruses was first recognized when viruses having chimeric noncapsid sequences were isolated from children exposed to the trivalent oral poliovirus vaccine (OPV) (3, 20, 23). Although most of the
vaccine-derived recombinants were produced by genetic exchange only
among the three vaccine strains (10), some recombinants
arose from exchange with other enteroviruses, including wild
polioviruses (15, 16, 27). Because OPV strains rarely spread
beyond the close contacts of vaccine recipients (2),
recombinant OPV-derived isolates generally have distinct crossover
patterns, indicating that the different recombinant genomes are the
products of independent evolutionary events (3, 10, 16, 23,
30).
Recombinants have also been detected among wild polioviruses (36,
49), some of which have spread extensively within human communities (49; H. G. A. M. van der
Avoort, personal communication). The key epidemiologic properties of
wild poliovirus recombinants, such as association with paralytic
poliomyelitis (polio) and the capacity for extensive circulation, are
essentially indistinguishable from those of their wild parents
(49). Indeed, for wild polioviruses, the distinction
between recombinant and nonrecombinant genomes appears to be arbitrary.
In this report, we describe a group of type 1 wild-vaccine strain
recombinants that had circulated widely in China from 1991 to 1993. The
recombinants were first isolated from patients with paralytic polio in
northern China in April 1991, following the peak polio epidemic
years of 1989 to 1990. All of the wild-vaccine recombinants appear to
be derived from a single infection, as each had a homologous
367-nucleotide (nt) block of sequences, spanning the VP1/2A junction,
that was derived from the Sabin type 1 OPV strain (LSc 2ab). Because no
substitutions were found in the Sabin 1-derived sequences of the
earliest recombinant isolates, it is likely that the recombinants were
detected shortly after the occurrence of the original recombination
event. By analysis of the pathways of evolution of the VP1 and 2A genes
(nt 2480 to 3832) of the recombinant isolates, in combination with the epidemiologic data, we followed the spread of the recombinant virus
over a 30-month period from northern China to much of the rest of the country.
Viruses.
Type 1 polioviruses (Table
1) were isolated by standard methods
(45) in the laboratories of the Provincial Epidemic
Prevention Stations of China. Isolates were initially characterized by
neutralization with hyperimmune antisera, followed by hybridization
with Sabin strain-specific (5) and wild genotype-specific
(6, 50) RNA probes and partial (150-nt) genomic sequencing
across the junction of the VP1 and 2A genes (49). Viruses
were propagated in RD cell (human rhabdomyosarcoma cell line; ATCC
CCL136) monolayers for extraction of poliovirus RNA.
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Molecular Evolution of a Type 1 Wild-Vaccine Poliovirus
Recombinant during Widespread Circulation in China

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
2 substitutions per synonymous site
per year) over the entire VP1-2A interval. Distinct evolutionary
lineages were found in different Chinese provinces. From the combined
epidemiologic and evolutionary analyses, we propose that the
recombinant virus arose during mixed infection of a single individual
in northern China in early 1991 and that its progeny spread by multiple
independent chains of transmission into some of the most populous areas
of China within a year of the initiating infection.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
5' exonuclease
proofreading mechanisms (8, 9). Base misincorporation rates
in the range of 10
5 to 10
4 per base pair
per replication have been reported for numerous poliovirus alleles
(7, 9, 44). The high mutability of poliovirus genomes,
coupled with the frequent occurrence of genetic bottlenecks
(8) during poliovirus replication in the human intestine
(21, 31), results in exceptionally rapid rates of evolution
(~10
2 substitutions per site per year) during
person-to-person transmission (J. Jorba, L. De, J. Kim, and O. M. Kew, Abstr. 18th Annu. Meet. Am. Soc. Virol., p. 148, 1999). Most of
this evolution appears to be random genetic drift, as >80% of
nucleotide substitutions within the coding region
generate synonymous codons (14, 31, 36, 40;
Jorba et al., Abstr. 18th Annu. Meet. Am. Soc. Virol., 1999).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Type 1 poliovirus isolates sequenced in this study
Extraction of RNA and reverse transcription-PCR. Viral RNA was extracted from freeze-thaw lysates of infected RD cell culture supernatants using Trizol LS reagent (GIBCO-BRL, Gaithersburg, Md.). In vitro reverse transcription and PCR amplification were modified from methods described previously (47). Two pairs of PCR primers, H7S (sense; positions 2402 to 2421, 5'-TTTGTGTCAGCATGTAACGA-3') plus H2A (antisense; 3155 to 3174, 5'-GCTGCACCGTAAAGCGAATC-3') and H5S (3083 to 3102, 5'-TCGAACGCCTACTCACACTT-3') plus H1A (3884 to 3903, 5'-TTGTCTCCAATTTGCTGAGT-3'), were prepared to prime the amplification of two overlapping sequencing templates that together span the complete VP1 and 2A genes.
Nucleotide sequencing of PCR-amplified genome segments. Amplified PCR products were purified with a QIAQuick PCR purification kit (QIAGEN, Chatsworth, Calif.) and used directly for sequencing with the dideoxynucleotide method, using an ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction kit (Perkin-Elmer Applied Biosystems, Foster City, Calif.) and an automated DNA sequencer (model 377A; Perkin-Elmer Applied Biosystems). The four PCR primers and four additional sequencing primers (H4S [2717 to 2736, 5'-TTCTTTGCGCGGGGTGCATG-3'], H3A [2753 to 2772, 5'-GTGGTAGCCGAATTGTCCAC-3'], H6S [3410 to 3429, 5'-GTGTACACTGCAGGTTACAA-3'], and Q8A [3485 to 3504, 5'-AAGAGGTCTCTATTCCACAT-3']) (36) were used for sequencing the PCR amplicons. To minimize possible sequence ambiguities arising from base misincorporation during in vitro amplification, duplicate amplicons were independently amplified from the RNA templates, and the sense and antisense polarity sequences were determined on separate amplicons.
Phylogenetic analysis. Evolutionary trees were constructed from the VP1 and 2A sequences (nt 2480 to 3832) of the 34 recombinant isolates using the DNA Maximum Likelihood program (11), applying the HKY model of nucleotide substitution (17), contained in the PHYLIP 3.572c program package. Input sequences were randomized seven times, and 19,657 alternative trees (among the 7.3 × 1045 possible rooted trees for 34 sequences [12]) were compared by heuristic search. The tree with the highest log likelihood score was presented (12). For comparison, trees were also constructed by 10,000 steps of quartet puzzling under a maximum-likelihood algorithm using the program PUZZLE 4.0 (39), by a maximum-parsimony method (FITCH) (12), and by neighbor joining (12, 37). Trees were displayed using the program TreeView (34).
Estimation of the evolution rate of the VP1 and 2A genes. Rates of fixation of synonymous base substitutions into the VP1 and 2A genes were estimated from the sequence differences among 21 recombinant isolates for which the dates of specimen collection or onset of paralysis were available. The number of substitutions at synonymous sites (Ks) was computed according to the methods of Li et al. (28, 29) as modified by Pamilo and Bianchi (35), implemented in the program DIVERGE of the Wisconsin Package version 9.1 (Genetics Computer Group, Madison, Wis.). This method applies the Kimura two-parameter model (22) to correct for multiple substitutions at a site and to account for differences in substitution rates for transitions and transversions (estimated from the data set to be 8.0:1). Ks values from the root sequence (that of 3645/HB91) were plotted as a function of the time of specimen collection (time zero [24 April 1991]). The date of sampling for isolate 3648/HB91 was also set to time zero (actual sample date, 19 April 1991). When only the date of onset was available, the date of specimen collection was assumed to be 15 days after the onset date (the average observed interval between these dates when both dates were known). The rates of accumulation of synonymous substitutions were estimated by linear regression through the origin.
Numbering of nucleotide and amino acid positions. The coding sequences of Sabin 1, 3645/HB91, and 3653/HE91 were colinear, but each differed by a small number of insertions or deletions in their 5' untranslated regions (33; H.-M. Liu, unpublished results). To facilitate comparisons, numbering of the VP1-2A nucleotide positions of all isolates followed that described for Sabin 1 (33). Amino acid positions were indicated by the name of the viral protein and numbered consecutively from residue 1 of each protein. Substitutions were indicated by the following convention: original residue-position-substitution residue(s). For example, VP1:I018M,V indicates a substitution of isoleucine by methionine or valine at amino acid position 18 of VP1.
Estimation of the time of occurrence of the recombination
event.
The time of occurrence of the recombination between the
indigenous type 1 wild poliovirus and the Sabin type 1 vaccine strain was estimated by comparing the differences in the
non-vaccine-derived VP1 sequences (nt 2480 to 3270) of the earliest
recombinant isolates (3645/HB91, 3646/HB91, and 3648/HB91) and the most
closely related nonrecombinant type 1 wild isolate, 3653/HE91. A
maximum-likelihood point estimate for the time of divergence
(tdiv) for the isolates based on the rate of
evolution of synonymous VP1 nucleotides was calculated for each pair
using the relationship.
|
ntsyn is the number of synonymous VP1
nucleotide differences between the two isolates,
rsyn is the rate of accumulation of synonymous
substitutions in the interval compared (measured at 3.69 × 10
2 substitutions per synonymous site per year, or
1.01 × 10
4 substitutions per synonymous site per
day), ntsyn, total is the total number of synonymous sites
(274) in the interval compared, and
t is the time
interval between the dates of sample collection for the two isolates.
The 95% confidence interval for the point estimate is approximated by
the equation
|
Nucleotide sequence accession numbers. The nucleotide sequences of polioviruses determined in this study were submitted to the GenBank library under accession numbers AF11950 to AF11983.
| |
RESULTS |
|---|
|
|
|---|
Epidemiologic background. Following the large nationwide polio outbreak in 1989 (4,623 cases) and 1990 (5,065 cases), China strengthened its routine OPV immunization activities (nationwide coverage was estimated to be >90% by March 1991) and initiated a program of supplemental OPV immunization through national immunization days. Supplemental immunization began in the winter of 1990 to 1991, with the highest rates of OPV coverage achieved in the northern provinces Hebei, Henan, Shandong, and Hubei, where two full rounds of immunization were conducted in December 1990 and January 1991 (46). In response, polio cases fell rapidly, from 2,009 in 1991 to 2 in 1994 (43). In 1990, the patterns of poliovirus circulation in China were complex, with at least three indigenous type 1 genotypes and one indigenous type 3 genotype still endemic to the country (19, 26, 49). By 1994, only two cases associated with wild polioviruses were found; they occurred in widely separated provinces (Xinjiang and Hubei) and were associated with different type 1 genotypes (19).
A sensitive surveillance system was established in China in 1990 to monitor the impact of the intensified immunization activities (46, 48). Polioviruses were first isolated from clinical samples, taken from patients with acute flaccid paralysis, in the laboratories of the Provincial Epidemic Prevention Stations. Poliovirus isolates were then forwarded to the National Poliovirus Laboratory for molecular characterization (49). The type 1 wild-vaccine recombinants were first detected during preliminary molecular characterizations (49). Isolates were first screened using genotype-specific RNA hybridization probes targeted to variable sequences (nt 2482 to 2575) near the 5' end of the VP1 gene (6, 50). Isolates identified as wild by probe hybridization were further characterized by sequencing a 150-nt interval (nt 3296 to 3445) at the junction between VP1 and 2A (90 nt of VP1, 60 nt of 2A) (36). The sequences of most isolates were consistent with their initial identification as wild polioviruses; however, several isolates had sequences at the VP1/2A junction derived from the Sabin type 1 OPV strain (49).Genetic relationships of an early recombinant to other
polioviruses.
The complete VP1 and 2A sequences were determined
for an early wild-vaccine recombinant, 3645/HB91, isolated from a
specimen obtained from a polio patient in Hebei province on 24 April
1991 (Table 1). The sequences were unusual because they contained a
stretch of 367 nt spanning the VP1/2A junction that perfectly matched
those of Sabin 1. The first 791 VP1 nucleotides of the recombinant
closely matched (787 of 791, 99.5%) (Fig.
1; Table 2)
those of isolate 3653/HE91, obtained from a patient in neighboring Henan province whose paralytic symptoms first appeared on 15 October 1991 (Table 1). Isolate 3653/HE91 is a representative of a type 1 wild
poliovirus genotype that was widely distributed in China up to 1994 (49). The last 195 2A nucleotides of 3645/HB91 were unrelated to those of Sabin 1 (76.9% sequence similarity) or 3653/HE91 (73.8% sequence similarity) (Fig. 1; Table 2).
|
|
Sequence relationships among recombinant isolates. Sequences of the VP1 and 2A genes were determined for 33 additional vaccine-wild recombinants isolated in 10 different Chinese provinces from 1991 to 1993. All shared the 367-nt block of Sabin 1-derived sequence found in 3645/HB91. VP1 and 2A sequences of two other early isolates, 3646/HB91 and 3648/HB91, contained no base substitutions in the Sabin 1-derived interval and differed from those of 3645/HB91 only by a C2590T transition. The sequence data indicated a close link between the three corresponding cases, which occurred within 22 days of each other in communities separated by 150 to 300 km (Table 1). Apart from 3646/HB91 and 3648/HB91, all isolates were much more divergent from 3645/HB91, having from 2 to 13 substitutions in the Sabin 1-derived interval and from 9 to 36 substitutions in the flanking sequences.
Sequence relationships among the recombinant isolates in the VP1 and 2A genes were summarized in an evolutionary tree (Fig. 2) constructed using the DNA maximum-likelihood algorithm (11). Trees constructed using the quartet-puzzling (39), neighbor-joining (37), or maximum-parsimony (12) algorithms had very similar branch structures (not shown). The maximum-likelihood tree was rooted to the sequence of 3645/HB91, the isolate that appeared to be closest to the genetic founder of the recombinant lineages. All isolates were closely related; the most divergent pair, 5731/HA93 and 6337/FJ93, shared 94.4% nucleotide sequence similarity in VP1 and 2A genes.
|
Substitution patterns within the VP1 and 2A genes and
proteins.
Using the maximum-likelihood tree in Fig. 2 for
reference, and assuming that each substitution along any
given branch occurred only once, we propose that the tree
represents the pattern of fixation of a total of 369 nucleotide
substitutions from the root sequence. Most (314 of 369, 85%) of the
substitutions generated synonymous codons. Of the estimated 472 synonymous sites in the VP1 and 2A genes (35), 256 (54%)
had no substitutions, 133 (28%) had one substitution, 66 (14%) had
two substitutions, 13 (2.8%) had three substitutions, 3 (0.6%; at
positions 2905, 2914, and 3802) had four substitutions, and 1 (0.2%;
at position 2941) had five substitutions (Fig.
3). When more than one substitution
occurred independently at a site (i.e., along separate branches of the tree), they usually were parallel mutations. However, reverse mutations
to the residue originally found in 3645/HB91 occurred six times at five
sites (at positions 2537, 2560, 2815, 3556 [two independent
reversions], and 3682), and sequential nonreverse mutations (all
involving a transversion followed by a transition) occurred at three
sites (at positions 3140, 3346, and 3532). Overall, 89% (328 of 369)
of all nucleotide substitutions were transitions.
|
Rates of evolution of VP1 and 2A genes.
The rates of fixation
of nucleotide substitutions into synonymous sites were estimated for
different intervals within the VP1 and 2A genes for the 21 recombinant
isolates for which records were available on the dates of onset or
specimen collection (Table 1). The reference sequence (assigned zero
substitutions) was that of 3645/HB91, and time zero was 24 April 1991. The overall synonymous substitution rate for the complete VP1 and 2A
genetic interval was (3.73 ± 0.52) × 10
2
substitutions per synonymous site per year (Fig.
4A). The synonymous substitution rate for
the VP1 interval derived from wild type 1 poliovirus was (3.69 ± 0.64) × 10
2 (Fig. 4B), a rate similar to that
[(3.17 ± 0.67) × 10
2] for the Sabin
1-derived interval (Fig. 4C). Interestingly, a higher synonymous
substitution rate [(5.23 ± 1.16) × 10
2] was
found for sequences encoding the non-Sabin 1-derived 2A sequences (Fig.
4D). The synonymous substitution rate for the complete VP1 gene
[(3.45 ± 0.57) × 10
2] (data not shown),
representing the combined rates for the wild and Sabin 1-derived
sequences, are very similar to the rates of VP1 substitution that have
been reported previously (14, 21, 31; Jorba et al.,
Abstr., 18th Annu. Meet. Am. Soc. Virol., 1999). A slightly higher
synonymous substitution rate [(4.40 ± 0.70) × 10
2] was observed for the complete 2A gene (data not
shown).
|
Estimated time of occurrence of the recombinant event.
The
close sequence match (only four mismatches in the first 791 nt in VP1)
(Fig. 1) between the early recombinant isolate, 3645/HB91 (case onset
date, 15 April 1991), and the nonrecombinant isolate, 3653/HE91 (case
onset date, 14 October 1991), suggests that the recombinant viruses
were detected soon after the occurrence of the recombination event.
This view is reinforced by the observation that no substitutions were
found in the Sabin 1-derived sequences of 3645/HB91, 3646/HB91, and
3648/HB91. We estimated the time of divergence between 3645/HB91
and 3653/HE91 from the observed number sequence differences at
synonymous sites (3) in the first 791 nt of VP1 and the
average rate of evolution at synonymous sites in that interval (assumed
to be 3.69 × 10
2 per year [Fig. 4B]). The
maximum-likelihood point estimate of the time of divergence was
calculated to be ~49 days after the occurrence of the case associated
with 3645/HB91 (around 3 June, a date inconsistent with the
epidemiologic record). However, the 95% confidence interval for the
point estimate was from ~56 days before (around 19 February) to ~85
days after onset of the 15 April case. Similar maximum-likelihood
calculations based on the sequence differences between 3653/HE91 and
3646/HB91 and 3648/HB91 yielded point estimates for the dates of
divergence of 26 May and 13 May, respectively (also inconsistent with
the epidemiologic record), but earliest dates of divergence were
calculated from the 95% confidence intervals to be around 3 February and 21 January. By comparing the calculated range of
divergence times with the epidemiologic record, we estimate that the
recombination event most likely occurred between mid-January and late
March 1991 (the case associated with recombinant isolate 3646/HB91 had
the earliest onset date, 30 March 1991 [Table 1]). While this is
about the time of the first mass immunization campaigns in Hebei and
Henan, the exact source of the vaccine exposure is unknown, as routine OPV coverage was high in those provinces in 1991 (46).
Geographic distribution of recombinant lineages.
The pathways
of divergence from the root VP1 and 2A sequence shown in the tree (Fig.
2) also trace the spread of the recombinant lineages within China
(Fig. 5). The earliest isolates
(from March and April cases [Table 1]), having the closest
sequence similarity to 3645/HB91 (Fig. 2), were from the northern
provinces of Hebei (root cluster) and Henan (cluster A1). Recombinant
lineages had spread to the neighboring provinces of Nei Mongol and
Shanxi (cluster F1) by June 1991 and to the southern province of Fujian
(early G1 cluster isolates) by the following December. By the end of 1991, recombinant polioviruses were already circulating by multiple chains of transmission. For example, 1991 isolates in Henan were associated with clusters A1 and D, and 1991 isolates from Nei Mongol
were associated with clusters E and F1 (Fig. 2).
|
| |
DISCUSSION |
|---|
|
|
|---|
The findings of this study highlight the remarkable speed at which type 1 poliovirus lineages, derived from a single source, can spread in a large, polio-endemic country with a mobile population. All of the wild-vaccine recombinants described here appear to be derived from a common ancestor closely related to 3645/HB91. The ancestral recombinant most likely arose during the mixed infection of one person, possibly a child living in the vicinity of southern Hebei province in early 1991, who had concurrent exposure to indigenous wild type 1 poliovirus and OPV. The progeny of this one infection quickly radiated along multiple independent chains of transmission over a wide geographic area, involving communities separated by as much as 2,200 km, in provinces with a combined population of over 450 million. Recombinant isolates were first detected in the northern provinces Hebei, Henan, Nei Mongol, and Shanxi in the spring of 1991; by the following year, they were found in the southern provinces Fujian, Guangdong, Hainan, and Yunnan and in the central province Sichuan. Transmission of the recombinant probably extended to other provinces in China but was not detected because of gaps in surveillance. Further spread of the recombinant may have been limited because most families with young children in China do not travel outside the country. The recombinants found in eastern and central China were not detected elsewhere, as the contemporary type 1 poliovirus isolates from Xinjiang province in western China, and from the bordering countries of Kyrgyzstan, Tajikistan, Pakistan, India, Nepal, Thailand, and Vietnam, were members of other, unrelated genotypes (49).
The rapid spread of the recombinant lineages in China does not imply that the recombinants were any more transmissible than the preexisting lineages. If the transmissibilities of cocirculating lineages are nearly equivalent, then the main determinants of transmission would be various, essentially unpredictable, epidemiologic factors. For example, if the recombination event occurred early in the poliovirus season (before spring), the recombinant might have a greater chance to contribute more lineages to the following high-transmission season. Widespread population movements, which peak during the winter months in China, would favor wide dissemination of potentially new founder strains before the start of the next polio season.
It is uncertain whether the recombinants could have completely displaced the previous nonrecombinant genotypes within China, because their appearance and spread coincided with the implementation of intensified supplemental nationwide polio immunization campaigns. The last reported case associated with the recombinant virus occurred in late 1993, and the last reported case associated with any indigenous wild type 1 poliovirus in China occurred in early 1994 (43). The mass immunization campaigns of 1991 to 1994 were highly effective in stopping all wild poliovirus circulation in China, first in the temperate provinces of the north, then in the more tropical south, and finally in the west (48, 50).
The appearance of recombinant lineages, and their detection soon after the recombination event, allowed us to readily follow their transmission above the complex background of multiple cocirculating type 1 lineages in China (26, 49). All of the recombinants carried a well-defined genetic marker, derived from a discrete natural event, in the 367-nt block of sequence derived from Sabin 1. This extended marker is very stable to reversion as a complete block (however, it could be lost by subsequent exchange with other templates), and thus it differs importantly from individual variable nucleotide positions, where the patterns of substitution can be approximately reconstructed using statistical models (11, 39). Moreover, because the marker was recently derived from a vaccine strain with a standardized sequence (33), it was possible to make a reasonable estimate about the timing of the recombination event.
Several alternative recombination pathways could account for the VP1 and 2A sequence patterns of 3645/HB91. The simplest recombination mechanism would be the insertion by double crossover of Sabin 1-derived sequences into the genome of an indigenous wild type 1 poliovirus. This mechanism might appear to be ruled out because the nonrecombinant wild isolate (3653/HE91) with the highest VP1 sequence match (99.5%) to 3645/HB91 in the non-vaccine-derived interval had a low sequence match (77.4%) to 3645/HB91 in the non-vaccine-derived 2A interval. However, the non-vaccine-derived 2A sequences of 3653/HE91 were obtained by recombination with a third virus (Liu, unpublished). In contrast, non-vaccine-derived sequences of a 1989 epidemic isolate from Jiangxi, 1340/JX89, matched those of 3645/HB91 in both the VP1 (95.8% match) and 2A (88.1% match) intervals. Although these sequence similarities indicate that 1340/JX89 and 3645/HB91 had a recent common ancestry, divergence of the capsid sequences apparently occurred later than divergence of the 2A sequences (assuming that the evolution rates of the VP1 and 2A regions are similar and constant). Thus, the evolutionary relationships between capsid and noncapsid domains of wild polioviruses appear to be very complex.
The recombinants described here are unusual because they involve a crossover within the capsid region of the poliovirus genome. The best-characterized poliovirus recombinants are those isolated from persons exposed to trivalent OPV. Intertypic recombinants excreted by recent vaccinees generally have crossovers restricted to the noncapsid region (3, 10, 16, 23, 30). Intertypic recombinants with crossovers in the capsid region are apparently very rare, possibly because of structural incompatibilities (13). If this view is correct, the only poliovirus recombinants generated by a single crossover within the capsid region likely to retain high replicative fitness would be those derived by exchanges between polioviruses of the same serotype. However, homotypic natural infections involving different poliovirus genotypes are presumably rare, except for those involving wild and vaccine-derived polioviruses, as apparently occurred in northern China in 1991.
Recombination occurs frequently during poliovirus evolution (16). Many different wild poliovirus recombinants have been found in China and other countries. As one example, additional crossovers were detected in the noncapsid regions of several of the vaccine-wild recombinants that were isolated from 1992 and 1993 cases (H.-M. Liu, D.-P. Zheng, L.-B. Zhang, O. M. Kew, and M. A. Pallansch, Abstr. 19th Annu. Meet. Am. Soc. Virol., p. 114, 2000). Indeed, possibly the only sequences in poliovirus genomes that are uniquely derived from other polioviruses are those encoding the capsid proteins.
| |
ACKNOWLEDGMENTS |
|---|
We thank the virologists from the National Polio Laboratory Network of China for sharing their isolates with us. We thank Howard Gary for advice on statistical analysis of the evolution rate data, Jaume Jorba for helpful discussions on phylogenetic analyses, and Larry Anderson for review of the manuscript. The excellent technical assistance of Hong Zheng (CAPM) and Silvia Peñaranda, A. J. Williams, and Naomi Dybdahl-Sissoko (CDC) is appreciated. We thank the Task Force for Child Survival and Development for its cooperation and assistance.
Hong-Mei Liu was supported by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Respiratory and Enterovirus Branch, G-17, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333. Phone: (404) 639-2762. Fax: (404) 639-4011. E-mail: hdl1{at}cdc.gov.
Present address: Department of Biology, Georgia State University,
Atlanta, GA 30303.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Agol, V. I. 1997. Recombination and other genomic rearrangements in picornaviruses. Semin. Virol. 8:77-84[CrossRef]. |
| 2. |
Benyesh-Melnick, M.,
J. L. Melnick,
W. E. Rawls,
I. Wimberley,
J. Barrera-Oro,
E. Ben-Porath, and V. Rennick.
1967.
Studies on the immunogenicity, communicability, and genetic stability of oral poliovaccine administered during the winter.
Am. J. Epidemiol.
86:112-136 |
| 3. | Cammack, N. J., A. Phillips, G. Dunn, V. Patel, and P. D. Minor. 1989. Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology 167:507-514. |
| 4. | Cooper, P. D. 1968. A genetic map of poliovirus temperature-sensitive mutants. Virology 35:584-596[CrossRef][Medline]. |
| 5. | De, L., B. K. Nottay, C.-F. Yang, B. P. Holloway, M. A. Pallansch, and O. Kew. 1995. Identification of vaccine-related polioviruses by hybridization with specific RNA probes. J. Clin. Microbiol. 33:562-571[Abstract]. |
| 6. | De, L., C.-F. Yang, E. da Silva, J. Boshell, P. Cáceres, J. R. Gómez, M. Pallansch, and O. Kew. 1997. Genotype-specific RNA probes for the direct identification of wild polioviruses by blot hybridization. J. Clin. Microbiol. 35:2834-2840[Abstract]. |
| 7. |
de la Torre, J. C.,
C. Giachetti,
B. L. Semler, and J. J. Holland.
1992.
High frequency of single-base transitions and extreme frequency of precise multiple-base reversion mutations in poliovirus.
Proc. Natl. Acad. Sci. USA
89:2531-2535 |
| 8. | Domingo, E., and J. J. Holland. 1997. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51:151-178[CrossRef][Medline]. |
| 9. |
Drake, J. W.
1993.
Rates of spontaneous mutation among RNA viruses.
Proc. Natl. Acad. Sci. USA
90:4171-4175 |
| 10. | Driesel, G., S. Diedrich, U. Kunkel, and E. Schreier. 1995. Vaccine-associated cases of poliomyelitis over a 30 year period in East Germany. Eur. J. Epidemiol. 11:647-654[CrossRef][Medline]. |
| 11. | Felsenstein, J. 1981. Evolutionary trees from DNA sequences: a maximum likelihood approach. J. Mol. Evol. 17:368-376[CrossRef][Medline]. |
| 12. | Felsenstein, J. 1993. PHYLIP (phylogeny inference package), version 3.5c. Department of Genetics, University of Washington, Seattle. |
| 13. | Filman, D. J., R. Syed, M. Chow, A. J. Macadam, P. D. Minor, and J. M. Hogle. 1989. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J. 8:1567-1579[Medline]. |
| 14. |
Gavrilin, G. V.,
E. A. Cherkasova,
G. Y. Lipskaya,
O. M. Kew, and V. I. Agol.
2000.
Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model.
J. Virol.
74:7381-7390 |
| 15. |
Georgescu, M.-M.,
F. Delpeyroux, and R. Crainic.
1995.
Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus.
J. Gen. Virol.
76:2343-2348 |
| 16. |
Guillot, S.,
V. Caro,
N. Cuervo,
E. Korotkova,
M. Combiescu,
A. Persu,
A. Aubert-Combiescu,
F. Delpeyroux, and R. Crainic.
2000.
Natural genetic exchanges between vaccine and wild poliovirus strains in humans.
J. Virol.
74:8434-8443 |
| 17. | Hasegawa, M., H. Kishino, and T. Yano. 1985. Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. J. Mol. Evol. 22:160-174[CrossRef][Medline]. |
| 18. |
Hirst, G. K.
1962.
Genetic recombination with Newcastle disease virus, polioviruses, and influenza.
Cold Spring Harbor Symp. Quant. Biol.
27:303-309 |
| 19. | Kew, O. M., M. N. Mulders, G. Y. Lipskaya, E. E. da Silva, and M. A. Pallansch. 1995. Molecular epidemiology of polioviruses. Semin. Virol. 6:401-414[CrossRef]. |
| 20. | Kew, O. M., and B. K. Nottay. 1984. Evolution of the oral poliovaccine strains in humans occurs by both mutation and intramolecular recombination, p. 357-362. In R. Lerner, and R. Chanock (ed.), Modern approaches to vaccines. Cold Spring Harbor Laboratory, New York, N.Y. |
| 21. |
Kew, O. M.,
R. W. Sutter,
B. Nottay,
M. McDonough,
D. R. Prevots,
L. Quick, and M. Pallansch.
1998.
Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient.
J. Clin. Microbiol.
36:2893-2899 |
| 22. | Kimura, M. 1980. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16:111-120[CrossRef][Medline]. |
| 23. |
King, A. M. Q.
1988.
Preferred sites of recombination in poliovirus RNA: an analysis of 40 intertypic cross-over sequences.
Nucleic Acids Res.
16:11705-11723 |
| 24. | Kirkegaard, K., and D. Baltimore. 1986. The mechanism of RNA recombination in poliovirus. Cell 47:433-443[CrossRef][Medline]. |
| 25. | Krebs, O., and O. Marquardt. 1992. Identification and characterization of foot-and-mouth disease virus O1 Burgwedel/1987 as an intertypic recombinant. J. Virol. 73:613-619. |
| 26. | Li, J., T. Yoneyama, H. Yoshida, K. Yoshii, H. Shimizu, T. Miyamura, M. Hara, X.-H. Hou, H. Zheng, Y. Fang, L.-B. Zhang, and A. Hagiwara. 1995. Genetic analysis of wild type 1 poliovirus isolates in China, 1985-1993. Res. Virol. 146:415-422[CrossRef][Medline]. |
| 27. | Li, J., L.-B. Zhang, T. Yoneyama, H. Yoshida, H. Shimizu, K. Yoshii, M. Hara, T. Nomura, H. Yoshikura, T. Miyamura, and A. Hagiwara. 1996. Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine-associated paralytic patients. Arch. Virol. 141:1047-1054[CrossRef][Medline]. |
| 28. | Li, W.-H. 1993. Unbiased estimation of the rates of synonymous and nonsynonymous substitution. J. Mol. Evol. 36:96-99[CrossRef][Medline]. |
| 29. | Li, W.-H., C.-I. Wu, and C.-C. Luo. 1985. A new method for estimating synonymous and nonsynonymous rates of nucleotide substitution considering the relative likelihood of nucleotide and codon changes. Mol. Biol. Evol. 2:150-174[Abstract]. |
| 30. | Lipskaya, G. Y., A. R. Muzychenko, O. K. Kutitova, S. V. Maslova, M. Equestre, S. G. Drozdov, R. Perez Bercoff, and V. I. Agol. 1991. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. J. Med. Virol. 35:290-296[Medline]. |
| 31. |
Martin, J.,
G. Dunn,
R. Hull,
V. Patel, and P. D. Minor.
2000.
Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion.
J. Virol.
74:3001-3010 |
| 32. | Minor, P. D. 1990. Antigenic structure of picornaviruses. Curr. Top. Microbiol. Immunol. 161:121-154[Medline]. |
| 33. |
Nomoto, A.,
T. Omata,
H. Toyoda,
S. Kuge,
H. Horie,
Y. Kataoka,
Y. Genba,
Y. Nakano, and N. Imura.
1982.
Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome.
Proc. Natl. Acad. Sci. USA
79:5793-5797 |
| 34. |
Page, R. D. M.
1996.
TreeView: an application to display phylogenetic trees on personal computers.
Comp. Appl. Biosci.
12:357-358 |
| 35. | Pamilo, P., and N. O. Bianchi. 1993. Evolution of the ZFX and ZFY genes: rates and interdependence between the genes. Mol. Biol. Evol. 10:271-281[Abstract]. |
| 36. | Rico-Hesse, R., M. A. Pallansch, B. K. Nottay, and O. M. Kew. 1987. Geographic distribution of wild poliovirus type 1 genotypes. Virology 160:311-322[CrossRef][Medline]. |
| 37. | Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425[Abstract]. |
| 38. |
Santti, J.,
T. Hyypia,
L. Kinnunen, and M. Salminen.
1999.
Evidence of recombination among enteroviruses.
J. Virol.
73:8741-8749 |
| 39. | Strimmer, K., and A. von Haeseler. 1996. Quartet puzzling: a quartet maximum likelihood method for reconstructing tree topologies. Mol. Biol. Evol. 13:964-969. |
| 40. |
Takeda, N.,
M. Tanimura, and K. Miyamura.
1994.
Molecular evolution of the major capsid protein VP1 of enterovirus 70.
J. Virol.
68:854-862 |
| 41. | Tolskaya, E. A., L. I. Romanova, M. S. Kolesnikova, and V. I. Agol. 1983. Intertypic recombination in poliovirus: genetic and biochemical studies. Virology 124:121-132[CrossRef][Medline]. |
| 42. | Toyoda, H., M. M. Kohara, Y. Kataoka, T. Suganuma, T. Omata, N. Imura, and A. Nomoto. 1984. Complete nucleotide sequences of all three poliovirus serotype genomes: implication for genetic relationship, gene function and antigenic determinants. J. Mol. Biol. 174:561-585[CrossRef][Medline]. |
| 43. | Wang, K.-A., L.-B. Zhang, M. W. Otten, Jr., X.-L. Zhang, Y. Chiba, R.-Z. Zhang, T. Xu, X. Liu, M. Liu, Q.-L. Li, J.-J. Yu, and Z. Wang. 1997. Status of the eradication of indigenous wild poliomyelitis in the People's Republic of China. J. Infect. Dis. 175:S105-S112. |
| 44. | Wimmer, E., C. U. Hellen, and X. Cao. 1993. Genetics of poliovirus. Annu. Rev. Genet. 27:353-436[CrossRef][Medline]. |
| 45. | World Health Organization. 1997. Manual for the virologic investigation of poliomyelitis WHO/EPI/GEN/97.1. World Health Organization, Geneva, Switzerland. |
| 46. | Yang, B., J. Zhang, M. W. Otten, Jr., K. Kusumoto, T. Jiang, R. Zhang, L. Zhang, and K. Wang. 1995. Eradication of poliomyelitis: progress in the People's Republic of China. Pediatr. Infect. Dis. J. 14:308-314[Medline]. |
| 47. | Yang, C.-F., L. De, S.-J. Yang, J. R. Gómez, J. R. Cruz, B. P. Holloway, M. A. Pallansch, and O. M. Kew. 1992. Genotype-specific in vitro amplification of sequences of the wild type 3 polioviruses from Mexico and Guatemala. Virus Res. 24:277-296[CrossRef][Medline]. |
| 48. | Zhang, J., L.-B. Zhang, M. W. Otten, Jr., T. Jiang, X.-L. Zhang, R.-Z. Zhang, and K.-A. Wang. 1997. Surveillance for polio eradication in the People's Republic of China. J. Infect. Dis. 175:S122-S134. |
| 49. | Zheng, D.-P., L.-B. Zhang, Z.-Y. Fang, C.-F. Yang, M. Mulders, M. A. Pallansch, and O. M. Kew. 1993. Distribution of wild type 1 poliovirus genotypes in China. J. Infect. Dis. 168:1361-1367[Medline]. |
| 50. | Zheng, D.-P., L.-B. Zhang, X.-H. Hou, H. Zhu, M. Otten, D. R. Kilpatrick, M. A. Pallansch, and O. M. Kew. 1995. Molecular epidemiology of poliovirus in China in the epidemic period of 1989-1994. Chin. J. Virol. 12:289-298. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»